Affiliation:
1. Department of Epidemiology Emory University Atlanta Georgia USA
2. Department of Systems Populations and Leadership School of Nursing and The Center for Sexuality and Health Disparities, University of Michigan Ann Arbor Michigan USA
Abstract
AbstractIntroductionLong‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour.MethodsWe conducted an online, cross‐sectional survey of SGM people aged 15–34 years in the southern United States (n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI‐PrEP‐related outcomes and key demographic and behavioural characteristics.ResultsOverall, 68% of all participants (n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most (n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non‐binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non‐Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non‐Hispanic White participants.ConclusionsWillingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non‐Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation.
Funder
National Institute of Nursing Research
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health
Reference25 articles.
1. FDA approves first injectable treatment for HIV pre‐exposure prevention.U.S. Food and Drug Administration;2021.
2. Centers for Disease Control and Prevention.Preexposure prophylaxis for the prevention of HIV infection in the United States –2021 update clinical practice guideline.2021. Accessed April 18 2022.https://www.cdc.gov/hiv/pdf/risk/prep/cdc‐hiv‐prep‐guidelines‐2021.pdf
3. Vulnerable Periods: Characterizing Patterns of Sexual Risk and Substance Use During Lapses in Adherence to HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men
4. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
5. Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献